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ABSTRACT: Down syndrome (DS) is caused by the trisomy 21 genetic disorder, which produces a unique craniofacial
phenotype. The purpose of this research is to better understand how Epigallocatechin-3-gallate (ECGC) influences
the development of DS craniofacial phenotypes. Ts65Dn DS mouse models have been genetically modified to have 3
copies of numerous genes found on human chromosome 21, including DYRK1A, which plays a role in bone and brain
development. EGCG is a known inhibitor of Dyrk1a activity. For this study, pregnant Ts65Dn mice were treated with
200 mg/kg of ECGC twice daily on days 7 and 8 of pregnancy. It was hypothesized that EGCG treatment will reduce
Dyrk1a overexpression during development resulting in a measurable improvement in craniofacial morphology. To test
this hypothesis, three mouse samples were analyzed: Ts65Dn, Ts65Dn + EGCG, and euploid. Skulls were imaged
using high-resolution µCT at 6 weeks after birth. Anatomical landmark coordinates were measured from µCT images
using Amira software. Euclidean Distance Matrix Analysis was used to assess craniofacial shape variation among
samples. Results show that EGCG improves craniofacial morphology in treated Ts65Dn mice relative to untreated
baselines, but improvements vary by region for the cranial vault, face, base, and mandible. Being able to understand
how EGCG influences craniofacial development on a trisomic background is the first step in finding a way to improve
phenotypic development to potentially avoid health issues of the craniofacial complex associated with DS. These
results suggest that EGCG could be a useful therapeutic option.
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INTRODUCTION
Trisomy 21 (Ts21), also known as Down syndrome
(DS), is a genetic disorder where the body creates three
functional copies of chromosomes 21 as opposed to
the normal two. DS is associated with birth defects,
intellectual disabilities, and characteristic facial features.
Babies with DS are at increased risk of being born
with heart defects, intestinal malformations, visual
impairment, hearing loss, thyroid problems, and leukemia
(Stanford Children’s Health, 2018). Cognitive abilities
such as recognitions, making specific connections,
learning, memories, and reaction time are affected due to
the gene-dosage imbalance resulting from Ts21.
DYRK1A (dual-specificity tyrosine-(Y)-phosphorylationregulated kinase 1A) is a serine/threonine gene essential
for brain development and function, located on
chromosome 21 (Ogawa et al., 2010). This gene helps
with signaling and correct protein function. Because a
third chromosome is expressed, DYRK1A is overexpressed
in individuals with DS, which leads to defective cortical
pyramidal cell morphology, synaptic plasticity deficits,
and altered excitation/inhibition balance (Ruiz-Mejias
et al., 2016).
Dyrk1a has recently been connected to the regulation
of bone development, homeostasis, and reabsorption
(Blazek et al., 2010). Furthermore, Dyrk1a appears
to have a crucial role during central nervous system
development (CNS), via its regulation of multiple targets
in both the nucleus and the cytoplasm (Stringer et al.,
2017). The overexpression of DYRK1A is thought to
strongly contribute to several of the facial characteristics
and negative health problems that occur in individuals
with DS.
EGCG (Epigallocatechin 3-gallate) is an antioxidant
found in green tea and a natural inhibitor of DYRK1A
activity (Ogawa et al., 2010). Previous trials with EGCG
have shown improvement in the adaptive behavior and
brain-related changes in young adults with DS because
of EGCG’s ability to cross the blood–brain barrier to
inhibit DYRK1A (Wyganowska-Świątkowska et al.,
2018).
Ts65Dn mice have been genetically modified to have 3
copies of numerous genes found on human chromosome
21, including Dyrk1a. As a model of human Ts21,
Ts65Dn mice display a remarkably diverse array of
DS-like phenotypes, including performance deficits in
https://stars.library.ucf.edu/urj/vol10/iss2/2

different behavioral tasks and alterations in synaptic
plasticity and adult neurogenesis (Scott-McKean et
al., 2010). Genetically, genes homologous to those
found on human chromosome 21 are located on mouse
chromosome 16 in Ts65Dn mice, with 55% of these
genes being homologous to one another.
The objective of this investigation is to determine
whether EGCG treatment produces an improvement
in craniofacial development of Ts65Dn mouse models
that overexpress Dyrk1a in addition to numerous other
chromosome 21 genes. EGCG is administered during a
critical window of craniofacial development to maximize
potential therapeutic benefits. This research is a first step
in finding a way to improve phenotypic development to
potentially avoid health issues associated with DS.
METHODOLOGY
Pregnant Ts65Dn and euploid mice were force fed either
200 mg/kg of EGCG or H2O, twice daily on embryonic
day 7 and 8. Treated and untreated Ts65Dn and euploid
offspring were imaged at 6 weeks of age using microcomputed tomography (µCT; 35 mm resolution) to
assess whether early EGCG treatment rescued skull
morphology. In summary, µCT images were sent to the
Starbuck lab at UCF for morphometric analysis, and
µCT images were thresholded to visualize bone and
viewed as 3D objects using Amira software, an extendable
software system for scientific visualization, data analysis,
and presentation of 3D and 4D data, to assess presence
and absence of anatomical structures and to identify and
measure anatomical landmarks located on bone surfaces.
Anatomical landmarks are biologically meaningful
points that can be seen in every animal used to find
forms and measure proportions. Here we find multiple
skull and mandible landmarks as shown in Table 1. The
number of landmarks measured from each craniofacial
region includes 12 from the face, 13 from the vault, 7
from the base, and 10 from the mandible (Figure 1).
Eighty eight skulls and mandibles were landmarked and
compared. Seven Ts65Dn offspring and euploid offspring
from a Ts65Dn mother were treated with EGCG, 10
euploid offspring from a euploid mother were treated
with EGCG, and 5 euploid offspring from a Ts65Dn
mother and 11 euploid offspring from a euploid mother
received no treatment.
A Euclidean Distance Matrix Analysis (EDMA)
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was employed to calculate all unique linear distance
measurements between anatomical landmarks using the
following formula:
d_((A,B) )=√(〖〖(x〗_1-x_(2))〗 ^2+(〖y_1 〖- y〗_2)〗 ^2+(
〖 z_1- z_2)〗 ^2 )

Afterwards, an EDMA confidence interval testing
procedure (α ≤ 0.10) was carried out on a region by
region basis to identify local mean differences between
samples, which resulted in the comparison of 66 linear
distances for the face, 78 for the vault, 21 for the base,
and 45 for the mandible.
RESULTS
Table 2 summarizes local test results with the first twosample comparison, Euploid versus Ts65Dn (Figure 2),
acting as a baseline for expected differences between
genetically modified trisomic mice and disomic controls.
The second two-sample contrast, Ts65Dn+EGCG versus
Ts65Dn (Figure 3), compares trisomic mice treated
with EGCG in utero and untreated trisomic mice to
determine if and how EGCG influences craniofacial
morphology. If EGCG had no effect on Dryk1a and
craniofacial development, then no craniofacial differences
would be expected between the treated and untreated
trisomic mice. In reality, however, following EGCG
treatment the percentages of significant morphological
measures increased in the face, decreased in the base and
vault, and stayed the same in the mandible (although
specific local differences may vary despite having the
same percentage). These results suggest that EGCG
does alter typical Ts65Dn craniofacial morphology,
likely by reducing Dyrk1a overexpression associated
with trisomy. The last two-sample comparison, Euploid
vs. Ts65Dn+EGCG (Figure 4), tells us how different
disomic euploid controls are compared to trisomic
genetically modified mice treated with EGCG. If
EGCG is rescuing trisomic craniofacial morphology
to euploid levels, then we should see fewer significant
differences between these two samples relative to the first
baseline comparison. Clear improvement in craniofacial
morphology occurs across the craniofacial complex
in the base, face, mandible, and vault, suggesting that
EGCG has reduced the overexpression of Dyrk1a during
development to ameliorate craniofacial morphogenesis
and growth.

Published by STARS, 2019

DISCUSSION
Ts65Dn mice models were specifically made in order
to study the effects of DS, including the overexpression
of Dyrk1a. EGCG was able to significantly change the
morphological measurements of the Ts65Dn mice skulls
and have a positive phenotypic effect, likely through the
reduction of Dyrk1a overexpression. A low number of
significant differences were also seen between the last
two-sample comparison, Euploid vs. Ts65Dn+EGCG.
This sample compares disomic mice to trisomic mice
that were treated with EGCG. Fewer differences
suggests that EGCG is helping to rescue the craniofacial
phenotype relative to untreated Ts65Dn mice, which are
very different from euploid controls.
Previous studies of EGCG have also recorded positive
results on the cognitive deficits of the overexpression
of Dyrk1a and improvement of behavior. For example,
many Ts65Dn mice treated with EGCG for 1 month
had visuospatial learning and memory improvement
in addition to improvement of learning strategies
and reference memory (De la Torre et al., 2013).
Homocysteine (Hcy) is an amino acid that, when
produced in high amounts, can cause brain atrophy,
cognitive impairment, and dementia, among other
things (Smith et al., 2010), Hcy decreases in mice when
treated with EGCG (De la Torre et al., 2013). Having
a higher amount of Hcy is common in individuals with
DS because of Hcy’s connection between Dyrk1a (De la
Torre et al., 2013). In humans, improvement of episodic
and working memory was shown after a three month
treatment of capsules of EGCG as well as visual memory
recognition, psychomotor speed, and social functioning
(De la Torre et al., 2013).
The results from this experiment suggest that a high
dose of EGCG treatment in utero improves craniofacial
morphogenesis and growth. Additional research is
necessary to determine if EGCG is a viable therapy
option for individuals with DS to reduce health issues
associated with the craniofacial complex as well as how
long the treatment should be and what dosage should
be used. Since EGCG is a kinase inhibitor, additional
studies are also needed to determine if EGCG inhibits
other genes, aside from Dyrk1a. In addition, other areas
of the post-skeleton and brain should be studied to
determine if EGCG affects these regions too. Moving
into the future, a larger study of the effects of EGCG
over a longer time period will be useful to assess side
effects or complications. Differences between mice and
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humans also must be incorporated when evaluating
different doses of EGCG, side effects, and differences in
results both cross-sectionally and longitudinally.
CONCLUSIONS
This research was conducted to determine whether
EGCG treatment improves craniofacial morphology
in Ts65Dn DS mouse models. EGCG-treated mice
showed improved craniofacial morphology in the face,
vault, base, and mandible relative to untreated Ts65Dn
mice and exhibited fewer differences with euploid mice,
suggesting a positive effect from EGCG treatment
overall. These results suggest that EGCG may be a useful
therapeutic option for humans with DS, but additional
studies are necessary to determine the best treatment
timing and dosage.
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APPENDIX
Figure 1. Skull and mandible landmarks.
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Table 1. Skull and mandible anatomical landmark definitions.
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Table 2. Comparison table of percentages and fractions of significant differences where 0% equals no differences and
100% equals all measurements were significantly different when compared.

Figure 2. Significant results from the comparison of Euploid and Ts65Dn mice.
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Figure 3. Significant results from the comparison of Ts65Dn treated with EGCG and untreated Ts65Dn mice.
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Figure 4. Significant results from the comparison of euploid mice and Ts65Dn mice that were treated with EGCG.

Published by STARS, 2019

www.URJ.ucf.edu

29

9

The Pegasus Review: UCF Undergraduate Research Journal (URJ), Vol. 10 [2019], Iss. 2, Art. 2

THE PEGASUS REVIEW:

10.2: 21-30

UNIVERSITY OF CENTRAL FLORIDA
UNDERGRADUATE RESEARCH JOURNAL

REFERENCES
1. Blazek, Joshua D. et al. “Disruption of Bone
Development and Homeostasis by Trisomy in Ts65Dn
Down Syndrome Mice.” Bone 48.2 (2011): 275–280.
PMC. Web. 23 May 2018.

9. Wyganowska-Świątkowska, Marzena et al. “Can
EGCG Alleviate Symptoms of Down Syndrome by
Altering Proteolytic Activity?” International Journal of
Molecular Sciences 19.1 (2018): 248. PMC. Web. 11 June
2018.

2. De la Torre, Rafael et al. “Epigallocatechin-3-gallate,
a DYRK1A inhibitor, rescues cognitive deﬁcits in Down
syndrome mouse models and in humans.” Mol. Nutr.
Food Res. 2013, 00, 1–11. Web. 29 Oct 2018.
3. Ogawa, Yasushi et al. “Development of a novel selective
inhibitor of the Down syndrome-related kinase Dyrk1A.”
Nature Communications volume1, Article number: 86
(2010). doi:10.1038/ncomms1090. Web. 23 May 2018.
4. Ruiz-Mejias, Marcel et al. “Overexpression of Dyrk1A,
a Down Syndrome Candidate, Decreases Excitability
and Impairs Gamma Oscillations in the Prefrontal
Cortex.” Journal of Neuroscience. 30 March 2016,
36 (13) 3648-3659; DOI: https://doi.org/10.1523/
JNEUROSCI.2517-15.2016. Web. 23 May 2018.
5. Scott-McKean, Jonah Jacob et al. “The Mouse Model
of Down Syndrome Ts65Dn Presents Visual Deficits
as Assessed by Pattern Visual Evoked Potentials.”
Invest. Ophthalmol. Vis. Sci. 2010;51(6):3300-3308. doi:
10.1167/iovs.09-4465. Web. 11 June 2018.
6. Smith, David A et al. “Homocysteine-Lowering
by B Vitamins Slows the Rate of Accelerated Brain
Atrophy in Mild Cognitive Impairment: A Randomized
Controlled Trial.” Plos Journal. 8 Sept 2010. https://doi.
org/10.1371/journal.pone.0012244. Web. 29 Oct 2018.
7. Stanford Children’s Health. “Down Syndrome
(Trisomy 21).” Stanford Children’s Health (2018).
DOI:
http://www.stanfordchildrens.org/en/topic/
default?id=down-syndrome-trisomy-21-90-P02356.
Web. 23 May 2018.
8. Stringer, Megan et al. “Targeting trisomic treatments:
optimizing Dyrk1a inhibition to improve Down
syndrome deficits.” Molecular Genetics & Genomic
Medicine 2017; 5(5): 451–465 https://doi.org/10.1002/
mgg3.334. Web. 11 June 2018.

https://stars.library.ucf.edu/urj/vol10/iss2/2

www.URJ.ucf.edu

30

10

